DMRA
Damora Therapeutics, Inc
Damora Therapeutics, Inc historical holders
total: 1
Viking Global Investors Damora Therapeutics, Inc transactions over time
- Total transactions:
- 1
- New positions:
- 1
- Held since:
- 2026 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2026 Q1
Ole Andreas Halvorsen has been an institutional investor in Damora Therapeutics, Inc (DMRA) since 2026 Q1. According to 2026 Q1 report, Ole Andreas Halvorsen holds 2,311,082 shares with a market value of roughly $59.86M representing 0.17% of their equity portfolio. The fund/company first acquired DMRA in 2026 Q1, initially purchasing about 2.31M shares.
Does Ole Andreas Halvorsen still hold DMRA?
Yes, Ole Andreas Halvorsen continues to hold Damora Therapeutics, Inc (DMRA). According to their 2026 Q1 report, they maintain a position of 2,311,082 shares valued at approximately $59.86M, representing 0.17% of their equity portfolio.
When did Ole Andreas Halvorsen first invest in DMRA?
Ole Andreas Halvorsen first invested in Damora Therapeutics, Inc (DMRA) in 2026 Q1 at the reported quarter-end price of $25.90 per share, acquiring 2,311,082 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for DMRA?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Damora Therapeutics, Inc (DMRA) is approximately $25.90 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $25.90
DMRA transactions history by Viking Global Investors
1 result
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q1
|
0.17%
|
2,311,082
|
$25.90
|
$59,857,024
|
new
|
+0.17%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.